

Microbe-derived acetate suppresses NAFLD/NASH development via hepatic FFAR2 signalling in mice

Ryo Aoki
Masayoshi Onuki
Koya Hattori
Masato Ito
Takahiro Yamada
Kohei Kamikado
Yun-Gi Kim
Nobuhiro Nakamoto
Ikuo Kimura
Julie M. Clarke
Takanori Kanai
Koji Hase

Video Byte

Keywords: Microbiome, non-alcoholic steatohepatitis, NASH, non-alcoholic fatty liver disease, NAFLD, short-chain fatty acids, acetate, prebiotics, prebiotic, inulin, FFAR2, Blautia, Bacteroides, insulin resistance, metabolism, metabolic syndrome, mouse study, mice, insulin, liver, hepatic, gut microbiome, intestine, portal vein, diet

Posted Date: October 13th, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-967519/v1>

License:  This work is licensed under a Creative Commons Attribution 4.0 International License.
[Read Full License](#)

Abstract

In the US and east Asia, non-alcoholic fatty liver disease (NAFLD) affects at least a quarter of the population. This disease is the manifestation of metabolic syndrome in the liver and can progress to non-alcoholic steatohepatitis (NASH). The gut microbiome is likely a contributing factor in NAFLD development and progression. Recently, researchers sought to identify the mechanisms that link the two together. They used a high-fat/fructose/cholesterol diet (HFC) to induce NAFLD-like symptoms in mice and found that adding the prebiotic inulin to their diet ameliorated these symptoms. Inulin-fed mice had global changes to their microbiome, particularly elevated levels of the bacterial groups *Bacteroides* and *Blautia*. Inulin supplementation also increased their gut concentrations of short-chain fatty acids, like acetate. Further experiments found that species from *Bacteroides* and *Blautia* had a synergistic effect on acetate production, and that it was acetate, not other short-chain fatty acids like butyrate or propionate, that protected against NAFLD/NASH. Reducing the expression of the acetate receptor FFAR2 reduced the protective effect of inulin and may increase insulin resistance in the liver. These results suggest that there is a commensal microbiome-acetate-FFAR2 molecular circuit that improves liver insulin sensitivity and prevents the development of NAFLD/NASH.